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A growing body of literature suggests that exposure to the neurotropic parasite Toxoplasma gondii
(T. gondii) is associated with increased risk of mental disorders, particularly schizophrenia. However, a
potential association between T. gondii exposure and anxiety disorders has not been rigorously explored.
Here, we examine the association of T. gondii infection with both anxiety and mood disorders. Partici-
pants (n = 484) were drawn from the Detroit Neighborhood Health Study, a population-representative
sample of Detroit residents. Logistic regression was used to examine the associations between T. gondii
exposure (deﬁned by seropositivity and IgG antibody levels) and three mental disorders: generalized
anxiety disorder (GAD), posttraumatic stress disorder (PTSD) and depression. We found that T. gondii
seropositivity was associated with a 2 times greater odds of GAD (odds ratio (OR), 2.25; 95% conﬁdence
interval (CI), 1.11–4.53) after adjusting for age, gender, race, income, marital status, and medication. Indi-
viduals in the highest antibody level category had more than 3 times higher odds of GAD (OR, 3.35; 95%
CI, 1.41–7.97). Neither T. gondii seropositivity nor IgG antibody levels was signiﬁcantly associated with
PTSD or depression. Our ﬁndings indicate that T. gondii infection is strongly and signiﬁcantly associated
with GAD. While prospective conﬁrmation is needed, T. gondii infection may play a role in the develop-
ment of GAD.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Anxiety and mood disorders contribute substantially to the bur-
den of disease and disability in the United States. A recent national
study estimates that generalized anxiety disorder (GAD), posttrau-
matic stress disorder (PTSD), and major depressive disorder affect
5.7%, 6.8%, and 16.6% of adults in their lifetime, respectively
(Kessler et al., 2005). Studies have established a genetic contribu-
tion to these mental disorders (Hettema et al., 2001; Sullivan
et al., 2000; Xian et al., 2000). Yet, the mapping of direct paths from
gene to mental disorders has been slow and inconsistent, as only a
few genome-wide association studies have detected risk genes and
many putative gene ﬁndings have failed replication (Hamer, 2002).
More fundamentally, a large proportion of variation in mentalhealth remains unexplained by genetic factors. For these reasons,
discovery of new risk factors for mental disorders is crucial.
A growing body of epidemiologic literature has implicated
infections as novel risk factors for development of mental disorders
(Benros et al., 2013; Dalman et al., 2008). One pathogen of partic-
ular interest is the neurotropic parasite Toxoplasma gondii (T. gon-
dii). T. gondii is capable of reproducing asexually within any warm-
blooded animal but must return to its deﬁnitive host, the cat, to
undergo sexual reproduction, develop into infectious oocysts, and
return to the environment through fecal shedding (Carruthers
and Suzuki, 2007). Infection is transmitted to an intermediate host
(e.g., a rodent) or a dead-end host (e.g., a human) via ingestion of
tissues cysts in undercooked meat or oocysts in cat feces or con-
taminated soil, whereupon the parasite progresses to form latent
cysts in muscle and neural cells, including neurons, glial cells,
and astrocytes (Carruthers and Suzuki, 2007).
As T. gondii does not complete its life cycle until passing from its
intermediate rodent host to its deﬁnitive feline host, the ‘‘manipula-
tion hypothesis’’ posits that the parasite may be under selective
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transmission to the deﬁnitive feline host (Lafferty, 1999). Indeed,
T. gondii has been shown to profoundly alter anxiety in rodents, as
evidenced by increased activity, decreased fear of novel stimuli,
and diminished predator vigilance (Berdoy et al., 2000; Webster,
1994; Webster et al., 1994). Meanwhile, a broad range of other
behaviors related to learning (Vyas et al., 2007), social status
(Berdoy et al., 1995), and olfaction (Vyas et al., 2007) remain
unaffected.
While the neurologic effects of toxoplasmosis in congenitally-
infected or immunocompromised humans are well-established
(e.g., encephalitis in AIDS patients), infection among the immuno-
competent is generally considered relatively benign: the parasite
is never cleared from thenervous systembut cell-mediated immune
response suppresses pathogenic activity (Montoya and Liesenfeld,
2004). This ‘‘no harm done’’ assumption is now being reconsidered,
as growing evidence links T. gondii to several mental disorders
(Fekadu et al., 2010). Decades of serological investigations have cor-
roborated a relationship between T. gondii and schizophrenia
(Torrey et al., 2012). More recently, studies have implicated the
infection in mood disorders (e.g., depression, bipolar disease) and
suicidal behavior (Fekadu et al., 2010), while a small case-control
study suggests an association with obsessive–compulsive disorder
(Mimanet al., 2010). To ourknowledge, noprevious studyhas exam-
ined the association between T. gondii and either GAD or PTSD, and
none has investigated the parasite’s associationwith any diagnosed
anxiety disorder among individuals living in the community setting.
To address these gaps in the literature, we used data from the
Detroit Neighborhood Health Study (DNHS), a prospective, popula-
tion-based study of residents of Detroit, Michigan. The purpose of
this study was to examine whether T. gondii seropositivity and IgG
antibody levels were associated with three different mental disor-
ders, GAD, PTSD, and depression, in persons 18 years of age and
older living in Detroit, Michigan.2. Materials and methods
2.1. Study population
The DNHS is a longitudinal, population-based study designed to
investigate correlates of mental disorders in the city of Detroit. A
probability sample of 1547 individuals (aged P18 years) living
within the Detroit city limits participated in a baseline telephone
survey in 2008–2009. The DNHS was approved by the institutional
review board at the University of Michigan, and all participants
provided written, informed consent. Participants were adminis-
tered a 40 minute assessment via a telephone survey, which
included questions on socio-demographic characteristics and a
standardized assessment of GAD, PTSD, and depression. Wave 1
survey participants were representative of the Detroit population
in terms of age, gender, race, income, and educational attainment
(for more detailed information, see Uddin et al., 2010). All respon-
dents were invited during the phone interview to participate in the
biospecimen component of the study and 484 (31.3%) participants
provided venipuncture blood specimens that were tested for T.
gondii IgG antibodies. The socio-demographic characteristics of
the biospecimen sample were comparable to the overall study
sample with the exception of income and education levels, which
were lower among those who provided a biospecimen. In addition,
past year GAD, PTSD, and depression were statistically signiﬁcantly
more prevalent among those who provided biospecimens tested
for T. gondii-speciﬁc IgG versus those in the overall study sample,
where 11.4% vs. 7.7% had GAD (p = 0.01), 13.4% vs. 9.4% had PTSD
(p = 0.01), and 15.8% vs. 11.4% had depression (p = 0.01) in the past
year at baseline.2.2. Laboratory analyses
Serum samples were analyzed for T. gondii infection by standard
procedures. Sera were frozen and stored at70 C, then shipped on
dry ice (within four weeks) to the Stanley Laboratory of Develop-
mental Neurovirology, Baltimore, Maryland. The presence and
quantity of immunoglobulin G (IgG) serum antibodies to T. gondii
were measured by solid phase enzyme-linked immunosorbent
assays and with laboratory personnel unaware of the status of
the study participants (Wang et al., 2011; Yolken et al., 2011).
Reagents for these assays were obtained from IBL Laboratories,
Hamburg, Germany.
2.3. Measures
Participants were categorized in the followingmanner: (1) Sero-
positivity: participants with T. gondii IgG values <10 International
Units (IU) were dichotomized as seronegative and those with IgG
valuesP10 IU were categorized as seropositive; (2) Serointensity:
continuous IgG antibody levels were standardized such that a one
unit increase in T. gondii IgG antibody level represents the effect of
1 standard deviation change in T. gondii IgG antibody level; and (3)
Antibody level category: IgG antibody level was categorized as high
level (P20.2 IU), low level (10–20.2 IU), or seronegative (<10.0 IU).
History of GAD, PTSD, and depression during the past year was
assessed during the baseline telephone survey with validated
instruments based on the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) criteria (American Psychiatric
Association, 2000) as previously described (Uddin et al., 2010).
Brieﬂy, past-year GAD was assessed using the seven-item general-
ized anxiety disorder scale (GAD-7) (Spitzer et al., 2006). Each of
the seven symptoms was scored from 0 (not at all) to 3 (nearly
every day), with total scores ranging from 0 to 21. Respondents
who scored P10 were categorized as having past-year GAD.
Past-year PTSD was assessed using a modiﬁed version of the PTSD
checklist (PCL-C), a 17-item measure of DSM-IV symptoms of PTSD
(Weathers, 1996). Participants identiﬁed past exposure to 19
potential traumatic events (PTE) and described PTSD symptoms
related to two traumatic events: (1) the event identiﬁed by the par-
ticipant as the most traumatic and (2) a randomly selected PTE
experienced by the participant. PTSD was considered present if
all six DSM-IV criteria were met in reference to either the worst
event or the random event. Past-year depression was assessed with
the Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001).
The nine items on the PHQ-9 were scored from 0 (not at all) to 3
(nearly every day), with total scores ranging from 0 to 27. Past-year
depression was considered present if participants reported
depressed mood or anhedonia and the co-occurrence of at least
one additional symptom for ‘‘more than half the days’’ in a 2-week
period over the past year. One symptom, ‘‘thoughts that you would
be better off dead or of hurting yourself in some way,’’ was
included in the depression score if present, regardless of symptom
duration. A clinical reappraisal study (n = 51) demonstrated that
the identiﬁcation of individuals with GAD, PTSD, and depression
by the survey screening scales displayed high concordance for
diagnoses of GAD, PTSD, and depression obtained via in-person
clinical interviews (Uddin et al., 2010).
Covariates: Age in years was self-reported and treated as a con-
tinuous variable. Race was self-reported and individuals were cat-
egorized as White, African-American, and Hispanic/Other. Gender
was dichotomized as female and male. Household income was
self-reported as pre-tax family income and was categorized as
(1) less than $25,000, (2) $25,000–$50,000, or (3) greater than
$50,000. Marital status was categorized as married, divorced, sep-
arated, widowed, or never married. Medications were classiﬁed
according to the Center for Disease Control and Prevention Ambu-
Table 1
Demographic and clinical characteristics by Toxoplasma gondii serostatus, n = 484
(DNHS, 2008–2009).
Distribution of T. gondii exposure
Seropositive
(n = 128)
Seronegative
(n = 356)
P-valuea
Age, mean (sd) 57.2 (14.7) 49.5 (16.4) <0.01
Gender, n (%)
Female 69 (53.9) 217 (61.0) 0.16
Male 59 (46.1) 139 (39.0)
Race/ethnicity, n (%)
White 20 (15.6) 36 (10.2) 0.25
African–American 100 (78.1) 292 (82.5)
Hispanic/Other 8 (6.3) 26 (7.3)
Income, n (%)
Less than $25,000 63 (49.2) 184 (51.7) 0.79
$25,000–$50,000 28 (21.9) 78 (21.9)
Greater than $50,000 28 (21.9) 68 (19.1)
Education, n (%)
Less than high school 23 (18.0) 64 (18.0) 0.73
High school completed/GED 42 (32.8) 106 (29.8)
Some college 45 (35.2) 121 (34.0)
College graduate or graduate work 18 (14.1) 65 (18.3)
Marital status, n (%)
Married 37 (28.9) 74 (20.8) 0.03
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Prevention, 2009) and medication use was dichotomized as cur-
rently taking anti-parasitic (i.e., antiprotozoals, antimalarials),
anti-microbial (i.e., tetracyclines, sulfonamides and trimethoprim,
antiviral agents), immunologic (i.e., immunomodulators), and/or
central nervous system (i.e., antianxiety agents, antipsychotic/anti-
manics, antidepressants) medications, or not.
2.4. Statistical analysis
Statistical analyses were conducted using SAS, version 9.2 (SAS,
2008). Two-sided T-tests and chi-square tests were used to examine
bivariate associations between T. gondii serostatus, mental disor-
ders, and covariates of interest. Covariates were considered con-
founders based on a priori hypotheses regarding covariates that are
associated with T. gondii infection and predictive of the outcomes
of interest. Logistic regression models were used to estimate the
crude and confounder-adjusted odds ratio (OR) and 95% conﬁdence
intervals (CI) for the associationsbetween the T. gondii seropositivity
and serointensity (continuous and dichotomized IgG antibody lev-
els) and each mental disorder. The fully adjusted model included
age, gender, race, income, marital status, and use of medications
thought to alter both immune function and mental disorders.Divorced 29 (22.7) 74 (20.8)
Separated 4 (3.1) 25 (7.0)
Widowed 22 (17.2) 41 (11.5)
Never been married 36 (28.1) 142 (39.9)
Medication useb
Yes 21 (16.4) 46 (13.5) 0.41
No 107 (83.6) 296 (86.5)
a T-tests (two-tailed) for difference in means, Pearson chi-square tests of inde-
pendence for proportions, tests for demographic trends were calculated.
b Medications include: central nervous system medications, anti-parasitic and
anti-microbial medications, and/or immunologic.
Table 2
The association between Toxoplasma gondii seropositivity and mental health disorders
in the Detroit Neighborhood Health Study.
Mental disorder Toxo sero-status Odds ratio (95% conﬁdence interval)
Unadjusted Adjusteda
GAD Pos vs. Neg 1.41 (0.77–2.57) 2.25 (1.11–4.53)
PTSD Pos vs. Neg 1.18 (0.66–2.09) 1.68 (0.88–3.21)
Depression Pos vs. Neg 0.77 (0.42–1.37) 1.09 (0.57–2.10)
Abbreviations: GAD, generalized anxiety disorder; PTSD, post-traumatic stress
disorder.
a Adjusted model includes age, gender, race, income, marital status, and medi-
cation use.3. Results
3.1. Demographic and clinical characteristics by Toxoplasma gondii
serostatus
Demographic and clinical characteristics by T. gondii serostatus
are shown in Table 1. Of the 484 participants, approximately 26%
(n = 128) were T. gondii seropositive. Age and marital status were
statistically signiﬁcantly associated with T. gondii seropositivity.
There were no signiﬁcant associations between T. gondii seroposi-
tivity and gender, race, income, education, or medication use. Of
the 448 participants, 55 (11.4%) had GAD, 65 (13.4%) had PTSD,
and 76 (15.8%) had depression in the past year at baseline.
3.2. Association between T. gondii seropositivity and serointensity and
mental disorders
The crude and covariate-adjusted associations between T. gondii
seropositivity and GAD, PTSD, and depression are shown in Table 2.
In unadjusted models, there was no statistically signiﬁcant associ-
ation between T. gondii seropositivity and GAD, PTSD or depres-
sion. After adjusting for age, gender, race, income, marital status,
and medication use, seropositivity for T. gondiiwas associated with
a 2.25 times greater odds (95% CI, 1.11–4.53) (Table 2). T. gondii
seropositivity was not signiﬁcantly associated with PTSD or
depression after adjustment.
We next examined the relationship between serointensity (i.e.,
continuous IgG antibody levels) and each mental disorder. For
every one standard deviation increase in T. gondii antibody level,
there was a marginal increase in the odds of GAD (OR 1.13; 95%
CI, 0.99–1.28) in the adjusted model. When we restricted the anal-
yses to only seropositive subjects (n = 128), the trend remained the
same for GAD, but did not reach statistical signiﬁcance, potentially
due to small sample size. Serointensity was not signiﬁcantly asso-
ciated with increased odds of PTSD or depression.
3.3. Association between T. gondii antibody level category and mental
health disorders
To examine whether T. gondii antibody levels exerted a non-lin-
ear effect, we examined the association between high or low anti-body levels compared to seronegative status with each mental
disorder (Table 3). In fully adjusted models, individuals in the high
T. gondii antibody level category had an OR of 3.35 (95% CI, 1.41–
7.97) for GAD as compared to seronegative subjects. The OR for
GAD for individuals categorized in the low antibody level category
compared to those who were T. gondii seronegative was not statis-
tically signiﬁcant in the fully adjusted model. Neither high nor low
T. gondii antibody level category was signiﬁcantly associated with
PTSD or depression when compared to seronegative subjects.
4. Discussion
Our study is the ﬁrst to examine the association between T. gon-
dii infection and any diagnosed anxiety disorder among individuals
participating in a population-based study. We found that seropos-
itive individuals had more than twice the odds of reporting GAD
compared to seronegative individuals. Strikingly, individuals in
Table 3
The association between Toxoplasma gondii antibody level categories and mental
health disorders in the Detroit Neighborhood Health Study.
Mental disorder Level category Odds ratio (95% conﬁdence interval)
Unadjusted Adjusteda
GAD Pos Low vs. Neg 0.89 (0.36–2.20) 1.43 (0.54–3.81)
Pos High vs. Neg 1.98 (0.97–4.05) 3.35 (1.41–7.97)
PTSD Pos Low vs. Neg 0.96 (0.43–2.15) 1.29 (0.54–3.07)
Pos High vs. Neg 1.40 (0.68–2.87) 2.19 (0.96–5.04)
Depression Pos Low vs. Neg 0.61 (0.27–1.41) 0.86 (0.35–2.09)
Pos High vs. Neg 0.93 (0.45–1.92) 1.40 (0.60–3.25)
Abbreviations: GAD, generalized anxiety disorder; PTSD, post-traumatic stress
disorder.
a Adjusted model includes age, gender, race, income, marital status, and medi-
cation use.
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of GAD as compared to seronegative individuals, suggesting a
graded relationship between immune response to T. gondii and
odds of GAD. By examining the association between T. gondii and
GAD, PTSD, and depression, we were uniquely positioned to exam-
ine whether T. gondii was related to multiple anxiety and mood
disorders. Our novel ﬁnding that T. gondii was associated with
GAD but neither PTSD nor depression suggests that T. gondii is spe-
ciﬁcally associated with GAD in our study population.
Despite compelling evidence that T. gondii infection profoundly
alters the manner in which rodents perceive and respond to stress-
ful stimuli (Webster, 2007), only two previous studies have inves-
tigated whether T. gondii is related to human anxiety (Groer et al.,
2011; Miman et al., 2010). Groer et al. assessed whether T. gondii
seropositivity and serointensity were associated with anxiety
among a cohort of pregnant women enrolled in a study of postpar-
tum thyroiditis, as assessed by the Proﬁle of Mood Disorder States
(POMS), a non-clinical diagnostic screening instrument (Groer
et al., 2011). Similar to our study, the authors found a positive cor-
relation between T. gondii serointensity and the POMS tension-
anxiety subscale score (r = 0.31, p < 0.04). However, use of the
POMS limited Groer et al. to scoring participants on a 5-point anx-
iety scale, whereas our study utilized a validated survey instru-
ment that enabled us to assign subjects clinical diagnoses of
GAD. In addition, generalizability of their ﬁndings were limited
to pregnant women enrolled in a study of postpartum thyroiditis
(Groer et al., 2011), whereas we included a subset of individuals
drawn from a population-based sample in our study.
To our knowledge, only one prior study has examined associa-
tions between T. gondii and any anxiety disorder as diagnosed by
DSM-IV criteria (Miman et al., 2010). In a case-control study of
142 subjects, Miman et al. found that individuals with psychia-
trist-diagnosed obsessive–compulsive disorder (OCD) were more
likely to be seropositive for T. gondii than were healthy controls
(chi-square 12.12, p < 0.01). However, the authors did not report
continuous or categorical antibody levels. Overall, our study is
the ﬁrst to demonstrate that, in addition to a positive association
between T. gondii seropositivity and GAD, there may be a graded
relationship between T. gondii IgG antibody levels and odds of GAD.
While the underlying mechanisms by which T. gondii speciﬁ-
cally affects GAD but not PTSD or depression remain uncertain,
potential anxiogenic pathways include histopathological, immuno-
logical, and neuromodulatory alterations (Webster, 2007). Rodent
studies have failed to uncover a highly selective tropism of T. gondii
for a speciﬁc brain region; tissue cysts have been detected
throughout the brain, with observed distribution patterns varying
both between (Berenreiterova et al., 2011; Haroon et al., 2012;
Vyas et al., 2007) and within (Berenreiterova et al., 2011) studies.
However, cyst density does not appear homogenous across brain
regions (Berenreiterova et al., 2011), while a recent study suggeststhat cysts may preferentially persist and increase in number in lim-
bic regions known to mediate anxiety, including the amygdala and
hypothalamus (Haroon et al., 2012). In vivo studies of chronically
infected rodents indicate that T. gondii cysts may impede neuronal
function, as neurons harboring cysts demonstrate dendritic retrac-
tion (Mitra et al., 2013) and reduced uptake of the potassium ana-
logue thallium (Haroon et al., 2012).
Another intriguing possibility is that T. gondii may directly acti-
vate the dopaminergic system of its host. The T. gondii genome con-
tains an ortholog of tyrosine hydroxylase (Etkin et al., 2009), the
rate-limiting enzyme in dopamine biosynthesis. Brains of infected
mice demonstrate increased levels of dopamine and parasitic tyro-
sine hydroxylase, both of which localize to the cysts themselves
(Prandovszky et al., 2011). As dopamine is known to powerfully
potentiate anxiety expression in the amygdala (de la Mora et al.,
2010), the capacity to augment local dopaminergic signaling could
allow T. gondii to inappropriately activate anxiety circuitry even in
the absence of a highly speciﬁc tropism. This model is supported by
reports that infected rats demonstrate greater activation in amy-
gdalar and hypothalamic nuclei (House et al., 2011) and that the
dopamine receptor antagonist haloperidol suppresses behavioral
changes in infected rats (Webster et al., 2006). As human studies
have implicated both amygdalar (Etkin et al., 2009) and dopami-
nergic (Koenen et al., 2009; Rowe et al., 1998) disruptions in
GAD, parasitic neuromodulation in these limbic structures may
activate anxiety circuitry and precipitate the development of
human GAD. It is important to note that these pathways are shared
by both PTSD and GAD and that the association between high T.
gondii antibody level category and PTSD approached statistical sig-
niﬁcance in fully adjusted models. By deﬁnition, however, PTSD
requires the occurrence of an external, traumatic event to trigger
this outcome in individuals and is therefore less likely to be asso-
ciated with T. gondii infection compared to GAD, a diagnosis that
does not require an exogenous event.
Prior studies of the association between T. gondii and depression
have been derived primarily from small case-control studies in
which subsamples of individuals with depressive disorders were
included secondarily as controls to the primary outcome of inter-
est, e.g., schizophrenia or history of suicidal behavior (Arling
et al., 2009; Cetinkaya et al., 2007; Hamidinejat et al., 2010;
Hinze-Selch et al., 2007). In the study by Groer et al., the authors
found that while T. gondii seropositivity was not associated with
higher depressive symptoms in their cohort of pregnant women,
among those seropositive for T. gondii, IgG titer was positively cor-
related with the POMS depression (r = 0.37, p < 0.01) subscale score
after controlling for age and race (Groer et al., 2011). More
recently, however, Pearce et al. examined the association between
T. gondii seropositivity and history of depression as among a U.S.
population-based sample of persons age 15–39 years of age using
data from the National Health and Nutrition Examination Survey
III (Pearce et al., 2012). Consistent with our ﬁndings among indi-
viduals drawn from a population-based sample of Detroit resi-
dents, neither T. gondii seropositivity nor serointensity was
associated with depression.
Our study design was cross-sectional and we are therefore lim-
ited in our ability to assess causality. While a convergence of evi-
dence suggests that T. gondii exposure may contribute to anxiety,
it is possible that the altered behavior of individuals with GAD
increases the risk of exposure to T. gondii. To our knowledge, how-
ever, no data exist to suggest that GAD increases exposure to
undercooked meat or cat ownership, two main routes of T. gondii
infection. In addition, it is also possible that GAD-related stressors
could suppress host immunity, permit T. gondii reactivation, and
result in elevated T. gondii antibody levels. However, the speciﬁcity
of the observed relationship between high T. gondii antibody level
category and GAD but not PTSD or depression argues against non-
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Another limitation is our measurement of T. gondii exposure, as
we were unable to assess parasite strain, route, or timing of infec-
tion. Although it is difﬁcult to measure some of these parameters in
a population-based study, future research should strive to include
this information in assessment of T. gondii exposure in the commu-
nity setting. Last, reporting of comorbid conditions were only avail-
able for 74% of our participants (360/484). Using this subset, we
conducted sensitivity analyses to examine whether comorbidity
was a potential confounder of the associations of interest in this
study. First, we created a modiﬁed Charlson comorbidity index
using data from the subset of participants who had complete data
on 10 available health conditions included in the original Charlson
index (Charlson et al., 1994, 1987). The modiﬁed Charlson comor-
bidity index was not signiﬁcantly associated with either T. gondii
serostatus or any of the mental health outcomes. Therefore, the
comorbidity index did not meet the criteria for considering a con-
founder in our data (Rothman et al., 2012). Nonetheless, we con-
ducted a sensitivity analysis by adding in the comorbidity index
in the fully adjusted models for each of our outcomes. We observed
that the odds of having GAD among seropositive individuals
decreased slightly from 2.25 (95% CI, 1.11–4.53) to 2.16 (95% CI,
0.92–5.08). Among those in the highest antibody level category,
the odds of having GAD increased from 3.35 (95% CI, 1.41–7.97)
to 3.92 (95% CI, 1.41–10.87), suggesting that the association
between high antibody levels to T. gondii and GAD are robust to
control for comorbid conditions.
Our novel ﬁndings suggest that T. gondii exposure, particularly
among the highest antibody level category, is associated with
GAD but not PTSD or depression even after adjusting for important
covariates. Given the tremendous personal and societal burden of
GAD in the United States (Kessler et al., 2005), identifying a mod-
iﬁable risk factor for GAD would have major public health implica-
tions. Current interventions for reducing T. gondii infection, such as
sanitation of consumer meat, proper meat cooking, and hygienic
cat feces handling, have helped to lower prevalence in the United
States; yet, 1 in 10 people remain infected with T. gondii nationally
(Jones et al., 2007). Further reducing the incidence of infection and
reactivation will require an effective vaccine and safer chemother-
apeutics (Jongert et al., 2009). Future research is needed to eluci-
date underlying biological mechanisms and to prospectively
conﬁrm and investigate the observed relationship between T. gon-
dii exposure and GAD.Conﬂict of interest
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